CORONA Remedies Limited has informed the Exchange about Presentation
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CORONA Remedies reported strong FY26 results with revenue of Rs 1,403.2 Cr (up 17.3% YoY) and adjusted PAT of Rs 199.4 Cr (up 33.4% YoY). EBITDA margin expanded 85 bps to 20.9% while PAT margin improved 170 bps to 14.2%. The company grew at 2x the IPM growth rate (17.2% vs 8.6%), ranking 27th in the Indian pharmaceutical market. Key strategic moves include acquisition of Wokadine (Rank 2 in segment) from Dr. Reddy's and 7 brands from Bayer Zydus for infertility. The Bhayla facility received EAEU-GMP certification enabling entry into Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan markets (up to USD 25 billion opportunity). Chronic therapies now contribute 71.9% of revenue vs 28.1% acute, showing successful portfolio shift. Return ratios improved with ROE at 29.2% and ROCE at 40.8%.
Strong operational performance with margin expansion signals execution capability. The 2x IPM growth rate and improving return ratios are positive for shareholders. Strategic acquisitions and international certifications expand the addressable market, though higher borrowings (Rs 142.9 Cr current) warrant monitoring.